Drug Discovery Informatics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Drug Discovery Informatics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global drug discovery informatics market size reached US$ 3.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.6 Billion by 2028, exhibiting a growth rate (CAGR) of 11.0% during 2022-2028.

Drug discovery informatics is a technological solution used for analyzing and interpreting large volumes of biochemical data. The data is generated from the experiments conducted in clinical laboratories for research purposes and utilized for generating insights regarding the development of various drugs. It involves numerous software and hardware-based tools for sequencing, target data analysis, data visualization, docking, molecular modelling, database protection for drug discovery and development. As a result, it is widely used by healthcare institutions, pharmaceutical and biotechnology organizations and contract research organizations (CROs).

Significant growth in the healthcare and pharmaceutical industries across the globe represents one of key the factors creating a positive outlook for the market. Furthermore, the increasing prevalence of chronic medical disorders and the escalating requirement for effective solutions to treat rare diseases are also augmenting the market growth. Drug discovery informatics is widely used by pharmaceutical organizations for the analysis of new drug entities and handling of the biological information from multiple sources. Additionally, various technological advancements, such as the development of innovative Physiologically-based Pharmacokinetic (PBPK) Simulator platforms, which aid in predicting pharmacokinetic outcomes through modeling and simulation, are acting as other growth-inducing factors. In line with this, increasing investments by government and private healthcare institutions to develop orphan drugs is also contributing to the market growth. Other factors, including the rising geriatric population, along with extensive research and development (R&D) activities in the field of bioinformatics, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global drug discovery informatics market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on workflow, function, mode and end user.

Breakup by Workflow:

Drug Discovery

Drug Development



Breakup by Function:

Sequence Analysis Platforms

Molecular Modelling

Molecular Docking

Clinical Trial Data Management

Others



Breakup by Mode:

Outsourced

In-house



Breakup by End User:

Pharmaceutical Companies

Biotechnology Companies

Contract Research Organization (CROs)

Others



Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa



Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accenture Plc, Certara, Charles River Laboratories Inc., Collaborative Drug Discovery Inc., Eurofins DiscoverX Products, Infosys Ltd., International Business Machines Corporation, Jubilant Biosys Limited, Oracle Corporation, PerkinElmer Inc., Selvita and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

How has the global drug discovery informatics market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global drug discovery informatics market?

What are the key regional markets?

What is the breakup of the market based on the workflow?

What is the breakup of the market based on the function?

What is the breakup of the market based on the mode?

What is the breakup of the market based on the end user?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global drug discovery informatics market and who are the key players?

What is the degree of competition in the industry?